IMPORTANT SAFETY INFORMATION AND INDICATION
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common adverse reaction occurring in ≥1% of subjects in clinical trials was application site pain, such as burning or stinging.
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older.
References: 1. EUCRISA® (crisaborole) Full Prescribing Information. October 2017. 2. Data on file. Pfizer Inc. New York, NY.
Please see Full Prescribing Information.
PP-CRI-USA-1085-02 © 2018 Pfizer Inc.
All rights reserved. April 2018
For the treatment
of mild-to-moderate atopic dermatitis in patients 2 and older
The specific mechanism(s) of action of crisaborole
in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4.
EUCRISA is the first
and only steroid-free
topical PDE4 inhibitor.1
For topical use only. Not for ophthalmic, oral, or intravaginal use.
EUCRISA can be
applied to the skin
anywhere on the
face and body.1
Please see adjacent
IMPORTANT SAFETY INFORMATION and INDICATION.
If signs and symptoms of hypersensitivity occur,
discontinue EUCRISA immediately and initiate appropriate therapy. EUCRISA was studied in pivotal trials for 29 days and in an open-label safety extension study for up to 48 weeks.
EUCRISA can be used on
all skin tones and has no
limitations on duration